Clinical Trial: Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of procarbazine, lomustine, and vincristine followed by radiation therapy in treating adults who have supratentorial glioma.

Detailed Summary:

OBJECTIVES: I. Estimate the response rate of patients with newly diagnosed supratentorial low-grade glioma following neoadjuvant chemotherapy with PCV (procarbazine/lomustine/vincristine). II. Describe the toxicity of PCV. III. Determine the incidence of disease progression in these patients during PCV treatment.

OUTLINE: The following acronyms are used: CCNU Lomustine, NSC-79037 PCB Procarbazine, NSC-77213 PCV PCB/CCNU/VCR VCR Vincristine, NSC-67574 3-Drug Combination Chemotherapy Followed by Radiotherapy. PCV; followed by external-beam cranial irradiation using at least 6 MV photons.

Sponsor: Alliance for Clinical Trials in Oncology

Current Primary Outcome: Response rate [ Time Frame: Up to 5 years ]

Original Primary Outcome:

Current Secondary Outcome: Disease progression [ Time Frame: Up to 5 years ]

Original Secondary Outcome:

Information By: Alliance for Clinical Trials in Oncology

Dates:
Date Received: November 1, 1999
Date Started: July 1996
Date Completion:
Last Updated: July 12, 2016
Last Verified: July 2016